Propranolol Therapeutic Cheat Sheet
Propranolol, a nonselective β-adrenergic blocker introduced in the 1960s, remains a cornerstone therapy in cardiology for hypertension, angina, and migraine prophylaxis. It has since gained transformative use in dermatology following the serendipitous discovery of its efficacy in infantile hemangiomas (IH), becoming the first FDA-approved systemic therapy for proliferating IH in 2014 given its va …
Propranolol, a nonselective β-adrenergic blocker introduced in the 1960s, remains a cornerstone therapy in cardiology for hypertension, angina, and migraine prophylaxis. It has since gained transformative use in dermatology following the serendipitous discovery of its efficacy in infantile hemangiomas (IH), becoming the first FDA-approved systemic therapy for proliferating IH in 2014 given its va … 
Secukinumab is a recombinant human monoclonal immunoglobulin IgG1κ antibody that selectively targets interleukin-17A (IL-17A), a key effector cytokine in the Th17 pathway implicated in the pathogenesis of psoriasis. With its high target specificity, rapid onset, sustained efficacy, and favorable safety profile, secukinumab has become a mainstay in the treatment of psoriasis and other inflammatory … 
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo … 
Photosensitive skin conditions can result in cutaneous and systemic symptoms that can have a marked effect on quality of life due to ubiquitous UV exposure. Erythropoietic protoporphyria, for example, can cause severe photodermatitis, excruciating burning and neuropathic pain, nausea, and deep-rooted fear of sunlight that leads to debilitating lifestyle modifications such as remaining indoors. We … 
Colchicine, a microtubule polymerization inhibitor, was first described for use in treating joint pain and swelling in ancient Egypt and has since become a mainstay in the medical management of gout. Beyond its indicated uses, it has numerous off-label dermatologic applications, particularly for neutrophilic and autoimmune conditions. As a potent anti-inflammatory, colchicine requires careful lab … 